Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer

European Urology

Volumn 65, Issue 4, 2014, Pages 832-838

  Berruti, Alfredo ^a   Fassnacht, Martin ^b,g   Haak, Harm ^c   Else, Tobias ^d   Baudin, Eric ^e   Sperone, Paola ^f   Kroiss, Matthias ^g   Kerkhofs, Thomas ^c   Williams, Andrew R ^d   Ardito, Arianna ^f   Leboulleux, Sophie ^e   Volante, Marco ^f   Deutschbein, Timo ^g   Feelders, Richards ^h   Ronchi, Cristina ^g   Grisanti, Salvatore ^a   Gelderblom, Hans ⁱ   Porpiglia, Francesco ^f   Papotti, Mauro ^f   Hammer, Gary D ^d   Allolio, Bruno ^g   Terzolo, Massimo ^f   more..

^a UNIVERSITY OF BRESCIA   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant therapy; Adrenocortical cancer; Cushing syndrome; Mitotane

Indexed keywords

ADJUVANT THERAPY; ADRENOCORTICAL CANCER; CUSHING SYNDROME; MITOTANE;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CUSHING SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84894484398     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.11.006     Document Type: Article

References (20)

1. A. Berruti, E. Baudin, H. Gelderblom ESMO Guidelines Working Group Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl 7 2012 vii 131-8
2. I. Erdogan, T. Deutschbein, C. Jurowich German Adrenocortical Carcinoma Study Group The role of surgery in the management of recurrent adrenocortical carcinoma J Clin Endocrinol Metab 98 2013 181 191
3. I.G. Hermsen, T.M. Kerkhofs, G. den Butter Dutch Adrenal Network Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery Surgery 152 2012 50 56
4. P. Icard, P. Goudet, C. Charpenay, and B. Andreassian et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group World J Surg 25 2001 891 897
5. S. Hahner, and M. Fassnacht Mitotane for adrenocortical carcinoma treatment Curr Opin Investig Drugs 6 2005 386 394
6. M. Terzolo, A. Angeli, and M. Fassnacht et al. Adjuvant mitotane treatment for adrenocortical carcinoma N Engl J Med 356 2007 2372 2380
7. A. Berruti, M. Fassnacht, and E. Baudin et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel J Clin Oncol 28 2010 e401 e402
8. M. Volante, P. Sperone, and E. Bollito et al. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas Mod Pathol 19 2006 1563 1569
9. W. Fenske, H.U. Völker, and P. Adam et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma Endocr Relat Cancer 16 2009 919 928
10. S. Sbiera, S. Schmull, and G. Assie et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors J Clin Endocrinol Metab 95 2010 E161 E171
11. A. de Reyniès, G. Assié, and D.S. Rickman et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival J Clin Oncol 27 2009 1108 1115
12. M. Volante, M. Terzolo, and M. Fassnacht et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer Clin Cancer Res 18 2012 3452 3461
13. M. Volante, C. Buttigliero, E. Greco, A. Berruti, and M. Papotti Pathological and molecular features of adrenocortical carcinoma: an update J Clin Pathol 61 2008 787 793
14. M. Fassnacht, R. Libé, M. Kroiss, and B. Allolio Adrenocortical carcinoma: a clinician's update Nat Rev Endocrinol 7 2011 323 335
15. G. Abiven, J. Coste, and L. Groussin et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients J Clin Endocrinol Metab 91 2006 2650 2655
16. A. Berruti, M. Terzolo, and P. Sperone et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 12 2005 657 666
17. J. Bertherat, J. Coste, and X. Bertagna Adjuvant mitotane in adrenocortical carcinoma N Engl J Med 357 2007 1256 1257
18. G. Assié, G. Antoni, and F. Tissier et al. Prognostic parameters of metastatic adrenocortical carcinoma J Clin Endocrinol Metab 92 2007 148 154
19. M. Fassnacht, S. Johanssen, M. Quinkler German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification Cancer 115 2009 243 250
20. C.L. Ronchi, S. Sbiera, and E. Leich et al. Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis J Clin Endocrinol Metab 97 2012 E2251 E2260